Bioceros B.V. announces change of ownership
Utrecht, The Netherlands, February 17th, 2011 - Bioceros B.V. announces that it has successfully realized a change of ownership. This is the result of the purchase of the outstanding shares owned by Forbion, Thuja Capital and Biogeneration Ventures by existing shareholders and the management team.
Bioceros’ CEO, Dr. Bram Bout comments: “The financial round of 2008, which was led by Thuja Capital and Biogeneration Ventures, has allowed us to build a strong, independent service business and to lay the foundation for a product pipeline. We are therefore pleased and proud that we can offer our investors this exit. Bioceros will further grow its service business by expanding its technology platform and spin out its early-stage products in a separate legal entity.”
Dr. Mark de Boer (chairman) and Dr. Oscar Schoots, MBA, will remain members of the Supervisory Board of Bioceros.
Bioceros is a biotech company focusing on pre-clinical development of protein products, with an emphasis on monoclonal antibodies. Bioceros’ technology platform covers early pre-clinical development of monoclonal antibodies, including generation of monoclonal antibodies in mice, making high protein producing CHO and PER.C6® cell lines, assay development and pre-clinical manufacturing at 20L scale. This is all Quality Controlled, using state of the art serum-free culture media, such that the generated cell lines can be used for GMP manufacturing. Bioceros is preferred vendor of DSM Biologics and Crucell for PER.C6® cell line generation services.
Bioceros uses this technology platform to offer services to the industry and academia, and to develop its own pipeline of monoclonal antibody products.
Bioceros is located in Utrecht, the Netherlands. For more information, please visit www.bioceros.com or contact:
Remco M. Brandt
3584 CM UTRECHT
Phone: +31(0) 30-253 7910
Cell: +31(0) 6-1012 7709
Fax: +31(0) 30-253 2288
Publisher Contact Information:
+31(0) 30-253 7910
Company profile of Bioceros
Past press releases of Bioceros.